| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Sep'18 | Jun'18 |
|---|---|---|---|---|---|---|
Collaboration revenue | ||||||
16,503 | 16,977 | 0 | 0 | 0 | - | - |
Operating expenses: | ||||||
Research and development | ||||||
62,322 | 53,732 | 42,679 | 35,337 | 0 | 0 | 0 |
General and administrative | ||||||
12,824 | 10,233 | 8,212 | 6,286 | 0 | 0 | 0 |
Total operating expenses | ||||||
75,146 | 63,965 | 50,891 | 41,623 | 0 | 0 | 0 |
Loss from operations | ||||||
-58,643 | -46,988 | -33,581 | -29,988 | 0 | 0 | 0 |
Other income: | ||||||
Interest income, net | ||||||
4,489 | 4,666 | 3,685 | 2,327 | 0 | 0 | 0 |
Other expense, net | ||||||
- | - | 0 | - | - | 0 | - |
Total other income, net | ||||||
4,395 | 4,572 | 3,575 | 2,311 | 0 | 0 | 0 |
Loss before benefit from (provision for) income taxes | ||||||
-54,248 | -42,416 | -30,006 | -27,677 | 0 | 0 | 0 |
Benefit from (provision for) income taxes | ||||||
626 | 912 | 568 | 264 | 0 | 0 | 0 |
Net loss | ||||||
-54,874 | -43,328 | -30,574 | -27,941 | 0 | 0 | 0 |
Net loss per share, basic and diluted | ||||||
-0.55 | 5.11 | -0.30 | -4.73 | -2.77 | -7.00 | -6.16 |
Weighted average common shares outstanding, basic and diluted | ||||||
30,188 | 30,536 | 29,999 | 1,992 | 1,879 | 1,011 | 1,011 |
Comprehensive loss: | ||||||
Net loss | ||||||
0 | - | - | - | 0 | - | - |
Other comprehensive income: | ||||||
Unrealized holding gains on marketable securities | ||||||
590 | 44 | 0 | 0 | 0 | - | - |
Total other comprehensive income | ||||||
0 | - | - | - | 0 | - | - |
Comprehensive loss | ||||||
-54,284 | -43,284 | -30,527 | -27,900 | 0 | 0 | 0 |
AbbVie | ||||||
Collaboration revenue | ||||||
0 | - | - | - | 0 | - | - |
Janssen | ||||||
Collaboration revenue | ||||||
0 | - | - | - | 0 | - | - |
Collaboration revenue - related party | ||||||
Collaboration revenue | ||||||
- | - | 0 | 0 | - | - | - |
Collaboration revenue - other | ||||||
Collaboration revenue | ||||||
- | - | 0 | 0 | - | - | - |